For people with vitiligo and their caregivers
What this page helps you do
Vitiligo mainly changes pigment, but family history and other autoimmune conditions can be part of the wider clinical picture. Learn what those associations mean, what they do not mean, and how to prepare a focused conversation about further evaluation.
- Your task
- Understand the current definition, evidence boundary, practical burden, and questions that affect fit.
- The clinician boundary
- Diagnosis, assessment of activity and body sites, prescribing, monitoring, and personalized treatment decisions belong to a qualified clinician.
Does family history tell me whether I will get vitiligo—or what it will do?
No. Vitiligo can run in families, but its inheritance is complex. Family history is useful context for a clinician; it does not confirm a diagnosis, predict a person’s course, or mean another family member will necessarily develop it. Evidence
Why this matters
Current health sources describe contributions from multiple genes together with immune and environmental factors. A clinician may ask about vitiligo and other autoimmune conditions in close relatives because that history can add context to the assessment.
Does vitiligo mean I have another autoimmune condition?
No. Vitiligo is autoimmune, and some other autoimmune conditions occur more often among people with vitiligo, but an association does not diagnose another condition or mean that every person will develop one. Evidence Evidence Evidence
Why this matters
Patient resources and clinical guidance treat personal symptoms and a personal or family history of autoimmune disease as relevant context. Autoimmune thyroid disease is the association most consistently emphasized in the guidance used for this page.
Why does thyroid health come up in a vitiligo appointment?
Autoimmune thyroid disease is a well-recognized association with vitiligo. A UK clinical guideline recommends thyroid testing, while the US patient resource used here describes selected blood tests as a possible part of evaluation without publishing a thyroid-specific schedule. This page does not decide what applies to an individual. Evidence Evidence
Why this matters
The British dermatology guideline recommends thyroid testing in people with vitiligo. The NIAMS resource is US patient education, not a US screening guideline; it describes selected blood tests for associated autoimmune disease as one possible part of evaluation.
Can vitiligo involve hair or mucous membranes?
Yes. Hair in an affected area can lose pigment, and vitiligo can involve mucous membranes, such as the lips. Those changes still need clinical context rather than self-diagnosis from color alone. Evidence
Why this matters
MedlinePlus Genetics describes premature whitening of hair and loss of color in mucous membranes, including the tissue that lines the lips. These are pigment changes; hair whitening is not the same as hair loss.
When might a clinician consider further evaluation?
Further evaluation may enter the conversation when the history, symptoms, examination, or personal or family autoimmune history raises a specific question. The useful next step should have a stated purpose rather than being a fixed panel for everyone. Evidence Evidence Evidence
Why this matters
Vitiligo assessment begins with history and examination. NIAMS describes selected blood tests, an eye examination, or a biopsy as possible—not automatic—parts of evaluation, while clinical guidance considers relevant comorbidity and differential diagnosis.
Who and what do these sources describe?
This guide combines US patient education, a UK clinical guideline, and international expert recommendations. They describe group-level evidence and clinical practice; they do not predict an individual diagnosis, future condition, or correct testing plan. Evidence Evidence Evidence Evidence
Why this matters
The sources agree that broader personal and family health context can matter. The clinical documents are written for professional care, and the patient resources summarize rather than reproduce the underlying evidence.
Questions that can change the next decision
- For your clinicianWhich guideline applies in my care setting?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- For your clinicianDoes my age, history, or presentation fall outside the groups described here?Saving keeps this on your device and needs JavaScript, which is off in this browser.
Evidence and update context
This optional layer shows the evidence boundary reviewed for this page as of 2026-08-05.
- What this evidence supports
- Current health sources describe contributions from multiple genes together with immune and environmental factors. A clinician may ask about vitiligo and other autoimmune conditions in close relatives because that history can add context to the assessment.
- What it does not establish
- These sources do not identify one “vitiligo gene,” offer a routine predictive genetic test, or calculate an individual family member’s future. A remembered family pattern may also be incomplete or based on an uncertain diagnosis.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
- MedlinePlus Genetics, National Library of MedicinePatient education · independentIndependent source
- Published
- 2022-02-24
- SteadySkin last checked
- 2026-08-05
What this source can and cannot tell you
What this source supports
Supports patient-facing context on complex genetic susceptibility, family occurrence, associated autoimmune conditions, and possible pigment loss in hair and mucous membranes.
What it does not support
It does not predict inheritance or disease course for an individual, recommend genetic testing, diagnose a comorbidity, or prescribe a screening plan.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- Journal of the European Academy of Dermatology and VenereologyRegulatory / guideline · not independentRelevant relationship disclosed
- Published
- 2023-09-25
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
Why the independence label says this: The journal is the publisher. This label refers to extensive author relationships disclosed for the recommendation, not to the journal itself.
What this source supports
It supports current expert-consensus terminology, clinical assessment, disease-activity evaluation, treatment-goal discussion, and shared decision-making.
What it does not support
It is not independent comparative proof. It cannot diagnose a reader from a description or photograph.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- British Journal of Dermatology (Eleftheriadou V, et al.)Regulatory / guideline · independentIndependent source
- Published
- 2022-01-01
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
What this source supports
Supports the clinical history and assessment domains, evaluation of associated autoimmune conditions, its recommendation for thyroid function and antithyroid antibody screening, current classification context, treatment-option map, psychosocial assessment, medical photography and the limits of pediatric evidence.
What it does not support
It was designed for UK care and reviewed literature through May 2019; it does not establish a universal testing plan, prescribe an individual plan, or establish current US labeling or coverage.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- National Institute of Arthritis and Musculoskeletal and Skin DiseasesPatient education · independentIndependent source
- Published
- 2022-10-01
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
What this source supports
Supports a patient-facing description of clinician diagnosis using history and examination, possible use of a Wood lamp and selected tests, broad treatment categories, variable response and whole-person support.
What it does not support
It is educational context, not primary efficacy evidence, an online diagnostic method or a universal testing checklist.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.